On Monday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s shares declined -8.57% to $99.38.
BioMarin Pharmaceutical Inc. (BMRN), declared that it has reached a settlement agreement with Dr. Reddy’s Laboratories, Inc. (Dr. Reddy’s) that resolves patent litigation in the United States (U.S.) related to BioMarin’s Kuvan(R) (sapropterin dihydrochloride) 100mg oral tablets.
Under the terms of the settlement, BioMarin will grant Dr. Reddy’s a non-exclusive license to its patents related to Kuvan to allow Dr. Reddy to market a generic version of sapropterin dihydrochloride 100mg tablets in the U.S. for the indications approved for Kuvan starting at a confidential date in the future, but which is more than five years from recently, or earlier under certain circumstances. Additional details of the agreement remain confidential.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally.
H & R Block Inc (NYSE:HRB)’s shares dropped -2.47% to $35.16.
H&R Block (HRB) — The IRS issues more than 40 million penalties to taxpayers every year. Now, taxpayers are getting a new and improved message from the IRS when they receive notices about failure-to-file and failure-to-pay penalties. These notices comprise a new insert that clearly explains taxpayers’ options for requesting penalty relief, counting a little-known provision that many taxpayers qualify for. In fact, more than 9 out of 10 taxpayers who would have qualified for this penalty relief provision have traditionally failed to claim it — mostly because they didn’t know to ask for it.
That’s why H&R Block (HRB), the world’s largest consumer tax preparation company, has worked on behalf of taxpayers since 2011 to improve transparency. H&R Block offers services to assist taxpayers with penalties, counting a free consultation with a tax resolution expert to make sure the IRS notice is correct and to address the penalty and underlying issue.
H&R Block, Inc., through its auxiliaries, provides tax preparation, banking, and other services to the general public primarily in the United States, Canada, and Australia. The company offers assisted income tax return preparation and related services through a system of retail offices operated directly by the company or by franchisees; and online tax services, such as tax advice, professional and do-it-yourself (DIY) tax return preparation, and electronic filing services through its Website hrblock.com.
At the end of Monday’s trade, Incyte Corporation (NASDAQ:INCY)‘s shares dipped -10.75% to $95.16.
Incyte Corporation (Nasdaq: INCY) declared it will present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference on Thursday, October 1, 2015 at 3:15 p.m. (EDT) in New York.
The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. Investors interested in listening to the live webcast should log on before the start time in order to download any software required. A replay of the presentation will be accessible.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.
La Jolla Pharmaceutical Company (NASDAQ:LJPC), ended its Monday’s trading session with -14.45% loss, and closed at $25.99.
La Jolla Pharmaceutical Company ( LJPC) a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, recently declared the closing of its underwritten public offering of 2,932,500 shares of common stock at a public offering price of $38.00 per share, which comprises the exercise of the underwriters’ option to purchase up to an additional 382,500 shares of common stock. Gross offering proceeds are about $111.4 million, counting proceeds from the exercise of the underwriters’ option to purchase additional shares, before deducting customary underwriting discounts and commissions and offering expenses.
La Jolla intends to use the net proceeds from the offering for general corporate purposes, counting funding its ongoing and future clinical trials, and for general and administrative expenses.
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
